Currently browsing tag


Sanofi says LixiLan diabetes drug trials meet targets

France's Sanofi said on Sunday that two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe early next year. LixiLan consists of a single-injection combination of Lyxumia, a drug developed with Danish drugmaker Zealand Pharma, and Sanofi's Lantus. It targets patients suffering from type 2 diabetes.

India’s Dr Reddy’s in $350 million deal to buy eight U.S. drugs from Teva, Allergan

By Zeba Siddiqui MUMBAI (Reuters) – India’s second-largest drugmaker Dr Reddy’s Laboratories Ltd said it agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash to bolster its U.S. business. The deal is among Dr Reddy’s biggest acquisitions, and comes at a time when the company has been facing slowing growth in the United States, its largest market, due to regulatory troubles and fewer new drug approvals. The drugs Dr Reddy’s is buying are being divested by Israel-based Teva, the world’s largest maker of generic drugs, to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan’s generic drugs portfolio.

Contaminated Flint water among most expensive in the U.S.: report

(Reuters) – Residents of Flint, Michigan, one of the poorest cities in the United States, paid some of the nation's highest water bills even as the city failed to treat drinking water properly, leading to lead contamination, according to a report released on Tuesday. The annual water bill in Flint as of January 2015 was $864.32 for a household using 60,000 gallons a year, said Washington-based advocacy group Food & Water Watch. The rate remained high compared with many other cities even after a judge ordered Flint to reduce its rates by 35 percent and to stop charging a service fee.

India’s Cadila gets FDA warning for violating standards at 2 plants

India’s Cadila Healthcare Ltd said it had received a “warning letter” from the U.S. Food and Drug Administration for violating manufacturing standards at two of its production sites in India, sending its shares down 15 percent on Thursday. The company said its Moraiya and Ahmedabad facilities have been cited in the letter, and it is working on responding to the FDA concerns regarding the sites. None of Cadila’s products being sold in the United States use any raw materials made at the Ahmedabad plant, it added.

India’s Dr Reddy’s gets FDA warning on three drug plants

By Zeba Siddiqui MUMBAI (Reuters) – Dr Reddy’s Laboratories Ltd, India’s second-largest drugmaker by sales, said on Friday it has received a “warning letter” from the U.S. Food and Drug Administration over what the regulator has deemed inadequate quality control procedures at three manufacturing plants in southern India. The warning letter means Dr Reddy’s will not receive FDA approvals to sell drugs manufactured at the plants for now, a blow for business at a company which relies on the United States for a majority of its sales. The plants make a significant contribution to company sales, with one alone accounting for 10-12 percent, Dr Reddy’s said.

Bacon fans embrace the hog on cancer report, but futures take fright

“Give me two pounds of bacon,” said Roland Marks, 47, a software engineer, rolling his eyes. “I'll take my chances.” It is too early for consumer or retail market data to show what any longer term impacts of the report will be in the United States, or whether shoppers will shun the traditional Christmas ham this year, say industry analysts. The WHO took to Twitter, too, and also issued a statement to emphasize that its International Agency for Research on Cancer (IARC) review “does not ask people to stop eating processed meats,” but just indicates that cutting consumption can reduce the risk of colorectal cancer.

Companies struggle to get new medicines adopted across Europe

By Ben Hirschler LONDON (Reuters) – Pharmaceutical companies, currently enjoying a bumper wave of new drug launches, are struggling to get recently introduced products adopted in key European markets as governments bear down on costs. While a number countries have pledged in recent years to encourage the use of innovative medicines, Europe remains a much tougher market than the United States, prompting many companies to offer significant price discounts.

Simple coordination to slash ‘superbug’ infections

Simple coordination between hospitals, nursing homes and health authorities could slash the number of drug-resistant “superbug” infections and save thousands of US lives, experts said. Hospitals and nursing homes strive to control infections but rarely report to one another when a patient being transferred is carrying antibiotic-resistant bacteria, greatly increasing the risk of spreading infections, said a Centers for Disease Control and Prevention (CDC) report. “Antibiotic-resistant infections in health care settings are a growing threat in the United States, killing thousands and thousands of people each year,” said CDC Director Tom Frieden.

New Embassies Open Door to Cuba’s Health Care Triumphs

As President Obama proclaimed diplomatic relations between the United States and Cuba for the first time in 50 years, the World Health Organization (WHO) was simultaneously celebrating Cuba Wednesday as the first country ever to eliminate mother-to-child transmissions of HIV/AIDS and congenital syphilis. Dr. Roberto Morales, minister of public health and the first Cuban minister to come to the United States since 1952, visited Washington, D.C., to discuss the historic success. While the monumental public health achievement was the intended focus of his news conference, Obama’s news was critical to the process.